Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $17000.0.

  • Tg Therapeutics' Depreciation & Amortization (CF) rose 5454.55% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $47000.0, marking a year-over-year decrease of 5154.64%. This contributed to the annual value of $68000.0 for FY2024, which is 6777.25% down from last year.
  • Tg Therapeutics' Depreciation & Amortization (CF) amounted to $17000.0 in Q3 2025, which was up 5454.55% from $13000.0 recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Depreciation & Amortization (CF) peaked at $80000.0 during Q4 2021, and registered a low of $8000.0 during Q1 2025.
  • Over the past 5 years, Tg Therapeutics' median Depreciation & Amortization (CF) value was $59000.0 (recorded in 2021), while the average stood at $47473.7.
  • Per our database at Business Quant, Tg Therapeutics' Depreciation & Amortization (CF) skyrocketed by 9705.88% in 2021 and then crashed by 8493.15% in 2024.
  • Over the past 5 years, Tg Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $80000.0 in 2021, then dropped by 8.75% to $73000.0 in 2022, then plummeted by 47.95% to $38000.0 in 2023, then tumbled by 76.32% to $9000.0 in 2024, then soared by 88.89% to $17000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $17000.0 for Q3 2025, versus $13000.0 for Q2 2025 and $8000.0 for Q1 2025.